局部晚期非小细胞肺癌选择性个体化放射免疫治疗试验(SPRINT)
SPRINT试验纳入25例PD-L1肿瘤比例评分≥50%的局部晚期非小细胞肺癌患者,采用帕博利珠单抗诱导后风险适应性胸部放疗、再巩固帕博利珠单抗的无化疗方案,1年无进展生存率为76%,达到预设疗效目标,1年和2年总生存率分别为92%和76%。
要点
- PD-L1 TPS≥50%的III期或不可切除II期NSCLC患者接受帕博利珠单抗诱导、风险适应性放疗和巩固帕博利珠单抗,1年PFS率76%。
- 诱导帕博利珠单抗后12例(48%)达到部分或完全缓解,24例(96%)接受了根治性胸部放疗。
- 最常见的3级不良事件为结肠炎(n=2,8%)和食管炎(n=2,8%),未发生更高等级的治疗相关不良事件。
核心结论
- 帕博利珠单抗联合风险适应性放疗、不使用化疗,对PD-L1 TPS≥50%的局部晚期非小细胞肺癌是有前景的治疗方法。
研究设计与样本
- 该试验为SPRINT试验,纳入III期NSCLC或不可切除II期NSCLC且ECOG体能状态评分为0-1的患者。
- PD-L1 TPS≥50%的患者接受3个周期诱导帕博利珠单抗(200 mg,每21天一次),随后接受20次风险适应性胸部放疗(肿瘤或淋巴结代谢体积超过20 cc者给予55 Gy,较小病灶给予48 Gy),再接受巩固帕博利珠单抗以完成1年疗程。
- 主要研究终点为1年无进展生存率(PFS),次要终点包括诱导帕博利珠单抗后的缓解率、总生存(OS)和不良事件。
- 共纳入25例PD-L1 TPS≥50%的患者,中位年龄71岁,大多数患者(88%)为IIIA或IIIB期,中位PD-L1 TPS为75%。
主要发现
- 2例患者在诱导帕博利珠单抗期间出现疾病进展,2例患者因免疫相关不良事件在输注1次后停用帕博利珠单抗。
- 采用RECIST标准,12例患者(48%)在诱导帕博利珠单抗后达到部分或完全缓解。
- 24例患者(96%)接受了根治性胸部放疗。
- 1年PFS率为76%,达到预设疗效目标;1年和2年OS率分别为92%和76%。
- 最常见的3级不良事件为结肠炎(n=2,8%)和食管炎(n=2,8%),未发生更高等级的治疗相关不良事件。
关键数值与推荐
- PD-L1 TPS≥50%的患者接受诱导帕博利珠单抗200 mg,每21天一次,共3个周期。
- 风险适应性胸部放疗共20次:肿瘤或淋巴结代谢体积超过20 cc者给予55 Gy,较小病灶给予48 Gy。
- 巩固帕博利珠单抗以完成1年治疗疗程。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Standard therapy for locally advanced non-small-cell lung cancer (LA-NSCLC) is concurrent chemoradiotherapy followed by adjuvant durvalumab. For biomarker-selected patients with LA-NSCLC, we hypothesized that sequential pembrolizumab and risk-adapted radiotherapy, without chemotherapy, would be well-tolerated and effective. METHODS: Patients with stage III NSCLC or unresectable stage II NSCLC and an Eastern Cooperative Oncology Group performance status of 0-1 were eligible for this trial. Patients with a PD-L1 tumor proportion score (TPS) of ≥50% received three cycles of induction pembrolizumab (200 mg, once every 21 days), followed by a 20-fraction course of risk-adapted thoracic radiotherapy (55 Gy delivered to tumors or lymph nodes with metabolic volume exceeding 20 cc, 48 Gy delivered to smaller lesions), followed by consolidation pembrolizumab to complete a 1-year treatment course. The primary study end point was 1-year progression-free survival (PFS). Secondary end points included response rates after induction pembrolizumab, overall survival (OS), and adverse events. RESULTS: Twenty-five patients with a PD-L1 TPS of ≥50% were enrolled. The median age was 71, most patients (88%) had stage IIIA or IIIB disease, and the median PD-L1 TPS was 75%. Two patients developed disease progression during induction pembrolizumab, and two patients discontinued pembrolizumab after one infusion because of immune-related adverse events. Using RECIST criteria, 12 patients (48%) exhibited a partial or complete response after induction pembrolizumab. Twenty-four patients (96%) received definitive thoracic radiotherapy. The 1-year PFS rate is 76%, satisfying our efficacy objective. One- and 2-year OS rates are 92% and 76%, respectively. The most common grade 3 adverse events were colitis (n = 2, 8%) and esophagitis (n = 2, 8%), and no higher-grade treatment-related adverse events have occurred. CONCLUSION: Pembrolizumab and risk-adapted radiotherapy, without chemotherapy, are a promising treatment approach for patients with LA-NSCLC with a PD-L1 TPS of ≥50%.
引用
- Ohri N, Jolly S, Cooper BT, et al. Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT). J Clin Oncol. 2023. PMID: 37988638. doi:10.1200/JCO.23.00627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。